A

Azurity Pharmaceuticals

Reformulates established medicines into alternative doses

Head of Marketing - US Oncology

Full-Time
No salary listed
Expert
Bachelor's, Master's
Woburn, MA, USA
HybridHybrid or office-based, depending on location. Travel is approximately 20–30%.
Growth & MarketingMarketing Generalist & Management

About the job

Requirements
  • A bachelor's degree in Marketing, Life Sciences, Business, or a related field is required.
  • At least 12 years of experience in the pharmaceutical or biotech industry, including at least 7 years of U.S.-based in-line marketing or launch experience in oncology.
  • Proven ability to manage multiple brands or indications simultaneously.
  • Prior experience with direct reports and team management.
  • Experience managing profit and loss statements.
  • Leadership skills and the ability to manage appropriately in a fast-paced environment and influence without authority.
  • Experience managing financials, including budgets, gross-to-net calculations, and resource allocation.
  • Ability to develop executive-level updates and narratives.
  • Experience working in a fast-paced, evolving organization with a hands-on and collaborative approach.
  • Ability to lead and motivate cross-functional teams toward common goals in a fast-paced, evolving organization.
Responsibilities
  • Oversee marketing activities for all products within the oncology franchise and manage the brand team.
  • Lead the annual brand planning process and develop and execute integrated marketing plans for in-line and pipeline brands aligned with corporate and commercial objectives.
  • Manage day-to-day brand operations, including the timely development, production, and execution of campaigns, messaging, and materials.
  • Monitor brand performance, key performance indicators, and market dynamics to optimize marketing strategy and inform tactical pivots.
  • Develop short- and long-term forecasts with finance and forecasting teams.
  • Collaborate with the insights team on primary research and assessment of secondary research data to generate market insights and inform brand strategy.
  • Manage the topline revenue forecast and gross-to-net calculations.
  • Oversee a portfolio of products across pre-launch, launch, growth, and maturity stages.
  • Prioritize and allocate resources across brands to maximize impact and return on investment.
  • Ensure brand consistency while tailoring approaches to product-specific needs and market segments.
  • Work with sales training, commercial functional partners, medical, and legal teams to develop and implement commercial training for the franchise.
  • Assess the competitive marketplace to anticipate future changes and revise strategies accordingly.
  • Partner with the launch excellence lead to conduct cross-functional launch-readiness efforts for new indications or products.
  • Partner with Medical Affairs, Market Access, Sales, Regulatory, and external agencies to deliver compliant promotional and educational content.
  • Develop and manage North America launch timelines, training materials, and field-execution strategies.
  • Serve as a liaison between marketing and the field force to drive alignment on strategy and messaging.
  • Collaborate with external partners, agencies, and vendors to develop omnichannel marketing campaigns.
  • Engage with key opinion leaders and gather market insights to inform brand planning and positioning.
  • Lead a small team of brand leads.
Desired Qualifications
  • An MBA or advanced degree.
  • Experience in sales and other commercial functions.

About the company

A

Azurity Pharmaceuticals

View
cbWebsite

Azurity Pharmaceuticals reformulates approved drugs into patient-friendly dose forms, such as oral suspensions, to meet unmet needs and aid those who have difficulty swallowing or require precise dosing. It markets these proprietary medicines to healthcare providers, hospitals, and pharmacies, supporting access to tailored therapies across the U.S. The company differentiates itself by focusing on dose-form reformulations across cardiovascular, CNS, endocrine, GI, anti-infective, and oncology areas instead of developing new chemical entities. Its goal is to improve patient access, adherence, and outcomes by delivering safe, effective therapies in customized formulations.

Company Size

201-500

Company Stage

Growth Equity (Venture Capital)

Total Funding

$182.2M

Headquarters

Woburn, Massachusetts

Founded

2000

Get referred to Azurity Pharmaceuticals

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • September 28, 2026 FDA approval of Lamlique expands epilepsy and bipolar access.
  • June 25, 2026 Aprepitant Injectable Emulsion strengthened oncology and hospital-channel breadth.
  • The February 13, 2026 $1.1 billion continuation vehicle funds M&A and licensing.

What critics are saying

  • Heron's June 2, 2026 CINVANTI patent fight shows recurring Orange Book litigation risk.
  • The July 2025 cabozantinib lawsuit heads to consolidated Delaware trial on November 2, 2026.
  • One manufacturing or quality failure can shatter Azurity's hospital trust across 50 countries.

What makes Azurity Pharmaceuticals unique

  • Azurity sells ready-to-use formulations, not compounded drugs, across 11 therapeutic areas.
  • The March 2025 Covis acquisition added respiratory brands and pushed Azurity into 50+ markets.
  • Its 505(b)(2) playbook keeps producing differentiated labels, including Lamlique on September 28, 2026.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • 401(k) Company Match
  • 401(k) Retirement Plan
  • Paid Vacation
  • Paid Holidays
  • Hybrid Work Options
  • Professional Development Budget
  • Tuition Reimbursement
  • Wellness Program

Company News

PharmTech
Oct 16th, 2026
Q&A: patient-centric Drug Development should start at product definition.

Q&A: patient-centric Drug Development should start at product definition. Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use. Medication nonadherence remains one of the widest gaps between how a drug performs in clinical trials and how it performs in practice. The World Health Organization has estimated that adherence to long-term therapies in developed countries averages about 50%, and a review in identified regimen complexity, adverse effects, and health system factors, not patient behavior alone, among the drivers.[1,2] The FDA has also continued to formalize patient input in development, finalizing the third installment of its four-part Patient-Focused Drug Development guidance series in late 2025.[3] For formulation and manufacturing teams, the challenge is translating those priorities into. Ahead of his presentation at CPHI Worldwide 2026 (Oct. 6-8, Milan), Ron Scarboro, CEO of Azurity Pharmaceuticals, discussed why nonadherence should be examined as a design issue. Pharmtech: if medication nonadherence is a design problem, when should real-world use be evaluated? Scarboro: It should start when you define the product. PharmTech Group must ask early who will take this medicine, where they will take it, and what might make that difficult. That means bringing patient, clinical, formulation, regulatory, and commercial perspectives together. You can't anticipate every barrier, though. You may discover after launch that a dosing instruction is hard to follow consistently. Those observations should be treated as design information, rather than assuming the patient needs more reminders. Its medical science liaisons and medical strategists work with key opinion leaders and physicians to feed that back into development. What is the hardest trade-off when reformulating a proven therapy? The hardest part is changing the conditions of use while preserving confidence in how the medicine performs. A fasting instruction may be closely tied to how the drug is absorbed. A new formulation may remove that barrier, but it must meet the same applicable standards for exposure, safety, and efficacy. Convenience matters only if the medication continues to do its job. Getting there takes iterative formulation work, careful testing, and regulatory, clinical, and manufacturing input throughout. Every product must stand on its own evidence. If the data don't support the change, you change course. How can smaller companies make a reengineered therapy commercially viable? Start with a specific patient-use problem. Bring development, medical, regulatory, quality, manufacturing, supply, and commercial teams together early, and have them ask four questions. Can PharmTech Group make an improvement? Can PharmTech Group produce it reliably? Can PharmTech Group get it to the patient? Can PharmTech Group support it commercially? When these issues are examined one department at a time, the difficult decisions come late and become expensive. Smaller companies can work through partners or licensing, but someone must own the entire pathway, from the unmet need through approval, supply, and use. When is added supply chain robustness worth the cost? It depends on where the medicine will be stored, who will administer it, and what the supply chain and care setting can support. A specialist center is different from a community clinic or a patient's home. Robustness doesn't mean claiming performance outside validated conditions. It means designing and testing for the intended environment. Extra complexity is a cost, but so are damaged product and disrupted supply. What metrics should regulatory and quality teams track after approval? I would begin with complaints, packaging and administration issues, and whether the product meets quality standards through distribution. I would pair those with supply availability. Where data are reliable, I would add adherence and persistence. Approval is only a milestone. The real measure is whether the medicine makes a difference for the patient who depends on it every day. References * World Health Organization. Adherence to Long-Term Therapies: Evidence for Action. WHO; 2003. * Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487-497. doi:10.1056/NEJMra050100 * FDA. Patient-Focused Drug Development: Selecting, Developing, or Modifying Fit-for-Purpose Clinical Outcome Assessments. Final guidance. 2025.

GlobeNewswire
Sep 29th, 2026
Azurity Pharmaceuticals showcases growth and commercial momentum ahead of CPHI Milan 2026.

Azurity Pharmaceuticals showcases growth and commercial momentum ahead of CPHI Milan 2026. Recent approvals and international expansion underscore the company's evolution as a global specialty pharmaceutical company focused on reimagining medicine for real-world patient needs. Woburn, MA, Sept. 29, 2026 (GLOBE NEWSWIRE) - Azurity Pharmaceuticals, a privately held specialty pharmaceutical company, today highlighted continued momentum across its global business including a commercial presence in more than 50 countries and a diversified portfolio of medicines across 11 therapeutic areas. Building on a series of recent regulatory approvals, strategic partnerships, and portfolio investments, Azurity continues to accelerate access to medicines designed for the realities of everyday life. The update comes as pharmaceutical leaders prepare to gather for CPHI Milan, taking place October 6-8, 2026, where Azurity executives will share perspectives on the future of pharmaceutical innovation, commercialization, and supply chain collaboration. "Azurity was built on the belief that medicine should work in the realities of everyday life," said Ronald Scarboro, Chief Executive Officer, Azurity Pharmaceuticals. "What began as a mission to address unmet patient needs has grown into a global enterprise built to reimagine medicine for the real world. Our momentum reflects the power of an operating model designed to recognize opportunities others may have overlooked and turned them into meaningful solutions for patients around the world." Recent regulatory milestones, portfolio investments, and commercialization activities have expanded Azurity's capabilities across development, commercialization, and international market access. New additions to the portfolio, including Contrave(R) and Mysimba(R), reflect the company's disciplined approach to identifying high-potential assets and creating new opportunities to deliver value for patients, providers, and healthcare systems. The 2025 acquisition of Covis Pharma marked another important milestone, expanding Azurity's presence to more than 50 markets worldwide and enhancing its ability to bring differentiated medicines to patients around the world. Azurity's operating model brings together business development, formulation development, regulatory expertise, commercial execution, and lifecycle management. This integrated approach enables the company to identify opportunities, develop differentiated products, and support their availability across a range of conditions, dosage forms, care settings and markets. "Combining local market insight with global scale is increasingly important as healthcare systems evolve," said Ronald van der Rol, Chief Commercial Officer, Europe and International, Azurity Pharmaceuticals. "Across Europe and other international markets, we see opportunities to bring proven therapies to more patients, build meaningful local partnerships, and create sustainable value. Our model gives us scale, expertise, and flexibility to pursue those opportunities while responding to distinct needs of individual markets." Azurity executives will take the stage at CPHI Milan to address key challenges in medicine design and global supply, with three speaking engagements on the official program: * Ronald Scarboro, Chief Executive Officer, will deliver a presentation on how patient needs and real-world use can inform medicine design on October 6, from 11:00-11:30 a.m., at Packaging & Device Innovation, Hall 11, 11A49. * Gyan Singh, Senior Vice President of Operations, will join a panel discussion, bringing an operations perspective on supply chain integrity, strategic partnerships, and the reliable delivery of medicines to patients on October 7, from 4:15-5:00 p.m., at Supply & Formulation Excellence, Hall 2, Room 2A132. * Hardik Shah, Vice President of CMC Product Development, will join a roundtable titled "Accelerating Early Clinical Development" at NH Hotel Milano Fiera on October 7, from 6:00-7:00 p.m. All times are local to Milan. Visit Azurity at Integrated Pharma, Hall 7, Stand 7B129, to learn more about the company's portfolio, international operations, and approach to pharmaceutical development and commercialization. To connect during CPHI Milan, schedule a meeting with the Azurity team. About Azurity Pharmaceuticals Azurity Pharmaceuticals is a privately held global pharmaceutical company dedicated to redefining medicine for the real world. Azurity's first-in-class enterprise model challenges the status quo by rethinking how therapies are designed, delivered, and accessed. With more than 70 medicines across 11 therapeutic areas, Azurity's mission is fueled by a growing portfolio that reaches millions of people in more than 50 countries. Learn more at www.azurity.com and LinkedIn.

Associated Press
Sep 28th, 2026
Azurity Pharmaceuticals receives FDA approval for Lamlique oral suspension for epilepsy treatment

Azurity Pharmaceuticals has received FDA approval for Lamlique (lamotrigine) oral suspension, a ready-to-use liquid formulation for epilepsy treatment. The drug is approved for patients aged 2 years and older as adjunctive therapy for partial-onset seizures, primary generalized tonic-clonic seizures, and generalized seizures of Lennox-Gastaut syndrome. It is also approved for conversion to monotherapy in certain patients and maintenance treatment of bipolar I disorder in adults. Lamlique offers an alternative to solid oral dosage forms and does not require compounding or refrigeration. It is available in two strengths: 5 mg/mL and 25 mg/mL. Approximately 3.4 million people in the US have epilepsy, including over 450,000 children. Lamlique is expected to be available by year-end 2026.

MarketBeat
Aug 12th, 2026
PolyPid Q2 earnings call highlights.

PolyPid Q2 earnings call highlights. August 12, 2026 Key points. * FDA review advances: PolyPid's NDA for D-PLEX100 was accepted on July 27, 2026, with priority review and a Nov. 28 PDUFA target date. The company is preparing for a pre-approval manufacturing inspection. * Azurity partnership provides funding and commercialization support: The U.S. and Canada agreement includes $30 million in upfront and near-term milestone payments, more than $290 million in potential additional milestones, and tiered royalties. Azurity expects to launch D-PLEX100 in early 2027 if approved. * Financial position improved: PolyPid's second-quarter net loss narrowed to $7.8 million from $10 million a year earlier, while the subsequent Azurity payments strengthened liquidity and are expected to fund operations into 2028. * Five stocks to consider instead of PolyPid. PolyPid NASDAQ: PYPD said its second-quarter 2026 was marked by the FDA's acceptance of its new drug application for D-PLEX100 and a commercialization agreement with Azurity Pharmaceuticals covering the United States and Canada. D-PLEX100 is being developed to prevent surgical site infections in patients undergoing abdominal corrective surgery. CEO Dikla Czaczkes Akselbrad said the FDA accepted the company's NDA for filing on July 27, after the company completed its submission during the second quarter. The agency granted priority review and set a Prescription Drug User Fee Act goal date of Nov. 28, 2026. Akselbrad said the FDA identified no filing review issues in the acceptance notice. Priority review reduces the standard review timeline to six months from 10 months, according to the company. PolyPid expects an FDA pre-approval inspection of its manufacturing facility as part of the review process and continues to prepare for that inspection through mock audits and outside consultants. Azurity partnership adds upfront payments and potential milestones. On July 17, PolyPid entered an exclusive agreement with Azurity Pharmaceuticals to commercialize D-PLEX100 in the U.S. and Canada. PolyPid said it has secured $30 million in aggregate upfront and near-term milestone payments, consisting of a $15 million payment at signing and a further $15 million payment following FDA acceptance of the NDA. The agreement also provides PolyPid eligibility for more than $290 million in additional regulatory, launch and sales milestones. The company is entitled to tiered royalties on Azurity's net sales ranging from the mid-teens to mid-20s percentages. PolyPid will retain global manufacturing responsibility and will receive an agreed transfer price for each unit supplied to Azurity. Chief Operating Officer Ori Warshavsky said Azurity was selected after a competitive partnering process involving multiple prospective commercial partners. He cited Azurity's portfolio of more than 50 medicines, its hospital and surgical-channel presence, and relationships with more than 1,700 hospitals and academic institutions as factors supporting the selection. Azurity will lead commercial activities including sales force development, national account planning, medical affairs and pharmacy-channel work. PolyPid will retain global regulatory strategy and manufacturing responsibilities. The companies have established joint forums for medical, regulatory and commercial launch preparations, management said. Discover more Company News Space stocks report PolyPid expects Azurity to launch D-PLEX100 in the U.S. in early 2027, assuming regulatory approval. Management said the commercial rollout is expected to proceed hospital by hospital and integrated delivery network by integrated delivery network rather than reaching all target institutions immediately. Manufacturing, reimbursement and European plans. The company said its manufacturing site in Israel has passed four consecutive good manufacturing practice inspections, including an inspection by Israel's Ministry of Health in September 2025. Prospective commercial partners, including Azurity, also conducted on-site diligence of the facility during the partnering process, management said. In response to analyst questions, Akselbrad said PolyPid has had several communications with the FDA since filing the NDA, including discussions relating to expected audits, but did not provide a specific date for the agency's pre-approval inspection. Management said commercial launch metrics will include hospital adoption, pharmacy and therapeutics committee approvals, pilot usage by physicians, reimbursement progress and discussions with payers. If D-PLEX100 launches in early 2027, PolyPid expects to recognize revenue as it supplies vials to Azurity under the agreed transfer price, while royalty and milestone revenue would be recognized as applicable. Warshavsky said Azurity is pursuing a New Technology Add-on Payment, or NTAP, application for the next government fiscal year. He said FDA approval is not required before submitting an NTAP application, provided the product is under FDA review, and noted an October deadline. PolyPid also plans to submit a marketing authorization application to the European Medicines Agency during the third quarter of 2026. Akselbrad said the company held meetings during the quarter with the EMA rapporteur and co-rapporteur and characterized them as productive. She said the discussions did not identify issues requiring additional data or changes that would delay the planned submission timeline. Label expansion and pipeline opportunities. The Azurity agreement includes an Azurity-funded joint development framework intended to pursue label expansion opportunities beyond the initial abdominal surgery indication. Management identified cardiac procedures, including coronary artery bypass grafting, orthopedic procedures such as hip and knee replacement, and breast mastectomy and reconstruction as potential areas of interest. PolyPid also cited expansion into territories outside the U.S. and Canada and further development of its PLEX technology platform as longer-term growth drivers. Warshavsky said the company is exploring applications beyond infection prevention, including treatment applications and a long-acting metabolic program, but did not provide specific product details or development timelines. Second-Quarter financial results. Research and development expense was $6.1 million in the second quarter, compared with $6.2 million a year earlier. General and administrative expense fell to $1.3 million from $2.5 million, primarily due to lower non-cash expenses related to performance-based options. Marketing and business development expense was $0.5 million, compared with $0.7 million in the prior-year period. Net loss totaled $7.8 million, or $0.35 per share, compared with a loss of $10 million, or $0.78 per share, in the second quarter of 2025. For the first six months of 2026, net loss was $15.6 million, compared with $18.2 million in the prior-year period. As of June 30, PolyPid had $6.6 million in cash and cash equivalents, compared with $12.9 million in cash equivalents and short-term deposits at Dec. 31, 2025. CFO Jonny Missulawin said the subsequent $30 million in Azurity payments strengthened the company's capital position. Based on current plans and assumptions, PolyPid expects available resources, partnership proceeds and potential future proceeds to fund operations into 2028. About PolyPid (NASDAQ:PYPD). PolyPid Ltd is a clinical-stage biotechnology company focused on polymer-based drug delivery technologies designed to enhance the performance of therapeutic agents at mucosal surfaces. Leveraging its proprietary Mucoadhesive & Mucus-Penetrating (MMP) platform, PolyPid develops long-acting formulations for ocular, oral and pulmonary indications. Its lead candidates include OncoTears and OralTear, therapies targeting dry eye and dry mouth conditions, respectively, as well as Paclical, a polymer-formulated paclitaxel designed to improve tolerability and antitumor activity in oncology patients. Founded in 2003 and headquartered in Jerusalem, Israel, PolyPid has assembled an international patent portfolio covering key markets in North America, Europe and Asia. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Continue following MarketBeat Before you consider PolyPid, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PolyPid wasn't on the list. While PolyPid currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you'll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Nang Kuang Medicine Trading Limited
Jul 31st, 2026
Press release for Eklira entering China NRDL_AZ 06.23.2026.

Press release for Eklira entering China NRDL_AZ 06.23.2026. PP-EKL-7577-CHI-EN-v1 Nang Kuang Medicine Trading Limited and Azurity Pharmaceuticals Announce that Aclidinium Bromide Powder for Inhalation (marketed under the trademark Eklira(R) Genuair(R) is Now Included in China's National Reimbursement Drug List for Chronic Obstructive Pulmonary Disease Treatment [HongKong 7th December] - Nang Kuang Medicine Trading Limited and Azurity Pharmaceuticals announced that aclidinium bromide powder for inhalation (marketed under the trademark Eklira(R) Genuair(R) has been included in China's National Reimbursement Drug List (NRDL), improving patient access to Chronic Obstructive Pulmonary Disease (COPD) treatment. "The strategic partnership between Nang Kuang and Azurity is aimed at bringing important respiratory therapies to patients in China," said Zhao Bing, General Manager at Nang Kuang. "The medicines are specifically for the maintenance treatment of patients with COPD, which is a rapidly growing respiratory condition in China." Through this collaboration, Nang Kuang has also obtained long-term exclusive rights to commercialize aclidinium bromide/formoterol fumarate powder for inhalation (marketed under trademark Duaklir(R) Genuair(R) in the Chinese market. Nang Kuang will lead commercialization to ensure rapid access for patients across China. "Azurity is proud to partner with Nang Kuang to make these treatment options available to more people with COPD," said Ronald van der Rol, Chief Commercial Officer for Europe and International at Azurity Pharmaceuticals. "We strive to transform how medicine is experienced globally and this is an important milestone for expanding access to our growing portfolio of medicines." About Aclidinium Bromide Powder for Inhalation Aclidinium bromide powder for inhalation is an imported original medicine primarily used for long-term maintenance treatment of adult patients with COPD. Positive results from the AVANT Phase 3 clinical trial for aclidinium bromide/formoterol fumarate powder for inhalation were previously reported. The 24-week study achieved statistically significant and clinically important outcomes for all key endpoint measures of efficacy in adult patients with moderate-to-severe COPD. There was no new safety concerns raised in the study and the findings were consistent with the known safety profiles of aclidinium bromide and aclidinium bromide/formoterol fumarate. The study involved 1,060 adult patients with moderate-to-severe COPD, with 70% of participants enrolled from China across 48 local study sites. Aclidinium bromide powder for inhalation was approved in China in 2024. As of January 1, 2026, it is included in the National Reimbursement Drug List (NRDL) as a Category B drug. Core Drug Information - Generic Name: Aclidinium Bromide Powder for Inhalation (imported original) - Indication: For symptom control and reduction of acute exacerbations in patients with COPD. Recommended dosage: one inhalation twice daily. - Drug Category: Category B (effective from 2026) Explanation of Reimbursement Policy As a Category B drug, Aclidinium Bromide requires patients to pay a certain percentage of the cost out-of-pocket before the remainder is reimbursed under the outpatient chronic and special disease policy. The specific reimbursement rate may vary and depends on the hospital level and type of insurance coverage. Application Process for Outpatient Chronic and Special Diseases - As of January 1, 2026 Aclidinium Bromide is reimbursable under the NRDL Category B policy. - Chronic/Special Disease Designation: Patients may be required to provide their ID card, social security card/medical insurance code, and a diagnosis certificate (including lung function report and medical records) from a Grade II or higher hospital. Applications can be submitted online via the National Medical Insurance Service Platform APP, or in person at the medical insurance office of a county-level hospital or a government affairs hall. - Special Drug Registration (if required): Some high-cost drugs may require a "Five-Part Management" system. Patients must visit a designated respiratory specialist at an authorized hospital for assessment and to obtain a designation form. After an initial review by the hospital's medical insurance office and a final review by the medical insurance authority, the patient's record will be flagged in the system to enable direct settlement. - Designated Pharmacy Purchase and Settlement: The product may be dispensed through a designated hospital or specialty pharmacy using your social security card or electronic medical insurance credential. The settlement system is expected to automatically recognize your outpatient chronic/special disease benefits, and you will only need to pay the out-of-pocket portion. References Efficacy and safety of aclidinium/formoterol versus monotherapies and aclidinium versus placebo in Chinese and other Asian patients with moderate-to-severe COPD: The AVANT Phase 3 study. Respiratory Medicine, 2023; 218 https://www.resmedjournal.com/article/S0954-6111(23)00281-0/fulltext European Medicines Agency https://www.ema.europa.eu/en/medicines/human/EPAR/eklira-genuair About Nang Kuang Medicine Trading Co. Nang Kuang Group is a China-based, innovation-driven pharmaceutical company with a global outlook. Dedicated to improving patient care through high-quality therapies, Nang Kuang has built long-term partnerships with leading international pharmaceutical companies. Learn more at www.nangkuang-med.com. About Azurity Pharmaceuticals Azurity Pharmaceuticals is a privately held global pharmaceutical company dedicated to redefining medicine for the real world. Azurity's first-in-class enterprise model challenges the status quo by rethinking how therapies are designed, delivered, and accessed. With more than 50 medicines across 10 therapeutic areas, Azurity's mission is fueled by a growing portfolio that reaches millions of people in more than 50 countries. Learn more at www.azurity.com. Media Contacts Nang Kuang: [email protected] Azurity Pharmaceuticals: [email protected] (C) 2026 Nang Kuang Medicine Trading Co., Ltd. All rights Reserved. This press release contains forward looking statements, including statements regarding anticipated commercialization and patient access in China. These statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially.